ERNEXA THERAPEUTICS INC (ERNA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.31-4.86%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Reduce operating losses and cash burn: TTM OCF -19.6M vs target improvement from -2.26M.
Ernexa is advancing its cancer drug ERNA-101 toward a Q3 filing. The company plans to raise money by selling 19 million shares. It aims to fix Nasdaq listing problems. These steps could help it survive and grow.
Ernexa is losing money with no revenue yet. It faces a Nasdaq delisting risk. Key finance staff recently left. The company has not stopped cash losses. These issues could hurt its future.
The market prices in high growth optionality but no current profits. Our fair value is about $1.40 per share, reflecting risk and potential. We see limited progress on key risks.
Breaks if: Public offering fails to complete by 2026-Q2
Raise capital through a public offering facilitated by a placement agency agreement.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a high-risk scenario due to ongoing losses and weak recent performance. The current thesis is cautious, as the company is navigating significant operational challenges while being influenced by broader healthcare sector trends.
The market appears to have priced in a high level of fragility, given the expensive valuation relative to peers. However, the current valuation does not fully reflect the combination of weak performance and turbulent conditions.
Fundamentals are likely to remain under pressure, as the company continues to experience operating losses and cash burn. The elevated risk of an earnings miss adds to the uncertainty surrounding its financial trajectory.
The future of ERNA hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX, which could either support or hinder its recovery. Additionally, the company's ability to address its Nasdaq compliance and manage its capital needs will be critical.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Newly stated in 2026-Q1. The company entered a placement agency agreement to raise capital via a public offering of 19 million shares. Financials show continued net losses and negative cash from operations, indicating ongoing capital needs. The priority is newly stated and capital raising is in progress.
“Entered into a placement agency agreement for public offering of 19 million shares.”
Breaks if: Bid price falls below $1.00 per share next quarter
Continue efforts to satisfy Nasdaq listing requirements and avoid delisting.
Newly stated in 2026-Q1. The company received a Nasdaq notice for failing to maintain the minimum bid price of $1.00 per share. No revenue data is available, but net losses and operating losses have continued. The priority is newly stated and the regulatory risk remains unresolved.
“Received notice from Nasdaq for failing to maintain minimum bid price of $1.00 per share.”
Breaks if: Losses and cash burn worsen or stay at 2026-Q1 levels
Control operating losses and reduce negative cash flow from operations to improve financial stability.
Stated in 7 of last 7 quarters. Operating income worsened from negative $2.7M in 2024-Q4 to negative $5.59M in 2026-Q1, then improved to negative $4.1M in 2026-Q2. Cash from operations remained negative, ranging from $3.55M to $4.15M negative. The company continues to experience operating losses and cash burn, indicating limited progress in controlling costs.
“Operating income negative $4.1M and cash from operations negative $4.15M.”
“Operating income negative $5.59M and cash from operations negative $2.26M.”
“Operating income negative $2.1M and cash from operations negative $1.15M.”
“Operating income negative $1.99M and cash from operations negative $1.27M.”
“Operating income negative $2.5M and cash from operations negative $2.53M.”
“Operating income negative $2.73M and cash from operations negative $2.06M.”
“Operating income negative $2.7M and cash from operations negative $3.55M.”
Breaks if: IND filing delayed beyond Q3 2026
Over the next 1 to 3 years, ERNA's outlook is clouded by operational challenges and high risk, despite potential sector support. Not investment advice.